XRTX
XORTX Therapeutics·NASDAQ
--
--(--)
--
--(--)
XRTX Profile
Xortx Therapeutics Inc.
A clinical-stage biotechnology company focused on therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in renal indications
3710—33rd Street NW, Calgary, Alberta, T2L 2M1, Canada
--
XORTX Therapeutics Inc., was incorporated under the laws of Alberta, Canada on August 24, 2012 under the name ReVasCor Inc. On January 10, 2018, the company name was changed to "XORTX Therapeutics Inc.". The Company is a clinical-stage biotechnology company focused on identifying, developing and commercializing therapies for progressive kidney disease regulated by abnormal purine and uric acid metabolism in renal indications including ADPKD, AKI caused by coronavirus COVID 19 infection and T2DN.
